A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
Jean‐Pierre Delord, Guillem Argilés, Jérôme Fayette, Lori J. Wirth, Stefan Kasper, Salvatore Siena, Ricard Mesı́a, Rossana Berardi, Andrés Cervantes, Jeroen Dekervel, Sylvia Zhao, Yongjian Sun, Huai-Xiang Hao, Ralph Tiedt, Sergio Vicente, Andrea P. Myers, Lillian L. Siu
Topics & Concepts
CetuximabMedicineKRASColorectal cancerPharmacodynamicsInternal medicineAdverse effectOncologyPharmacokineticsResponse Evaluation Criteria in Solid TumorsEGFR inhibitorsEpidermal growth factor receptorToxicityPhases of clinical researchCancerMonoclonal antibodyPharmacologyAntibodyImmunologyColorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsHepatocellular Carcinoma Treatment and Prognosis